Toripalimab
Toripalimab is an immunotherapy medication classified as a PD-1 inhibitor. It works by blocking the PD-1 receptor on T cells, preventing tumor cells from using the PD-L1/PD-L2 pathway to suppress immune responses. This medication is primarily used to treat various cancers by helping the body's immune system recognize and attack cancer cells.
Toripalimab is a PD-1 blocking antibody used to treat certain cancers by helping restore the immune system's ability to fight tumor cells.
Key facts at a glance
- ATC
- L01FF13
- RxNorm
- 2669406
- Generic
- Toripalimab
- Class
- atc-l01
- Brands
- Loqtorzi
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second third trimesteravoid if possible
discontinue therapy if pregnancy occurs; consider risks vs benefits
regular fetal monitoring and ultrasound
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingdiscontinue breastfeeding
do not breastfeed during treatment and for at least 3 months after last dose
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
children adolescentsnot established
safety and efficacy not established in pediatric patients; use only in clinical trials
close monitoring in clinical trial setting
geriatric
elderly 65 yearsno dose adjustment required
can be used at standard dosing; monitor for immune-related adverse events
regular monitoring for adverse reactions
Use with caution and monitor for adverse effects.
renal_impairment
mild moderateno dose adjustment required
can be used at standard dosing in mild to moderate renal impairment
routine renal function monitoring
renal_impairment
severeuse with caution
limited data available; use only if benefits outweigh risks
close monitoring of renal function
Use with caution and monitor for adverse effects.
hepatic_impairment
mild moderateno dose adjustment required
can be used at standard dosing in mild to moderate hepatic impairment
routine liver function monitoring
hepatic_impairment
severeuse with caution
limited data available; use only if benefits outweigh risks
close monitoring of liver function
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Monoclonal antibody targeting PD-1 receptor
FDA approved indications
Therapeutic indications for toripalimab
Mechanism of action
Pharmacodynamic mechanism
FDA approval year
First FDA approval date for Loqtorzi
Toripalimab is used to treat multiple cancer types, including nasopharyngeal carcinoma, melanoma, and other solid tumors. It may be used alone or in combination with other cancer treatments depending on the specific cancer and treatment setting.
Toripalimab binds to the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 ligands on tumor cells. This prevents the tumor from suppressing T cell activity, allowing T cells to proliferate, produce cytokines, and attack cancer cells.
As an immunotherapy, toripalimab can cause immune-related adverse events affecting various organs including lungs, liver, kidneys, and endocrine glands. Patients should be monitored closely during treatment for signs of immune-mediated reactions. Infusion reactions may also occur.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy